Spring Bank Pharmaceuticals, Inc.
35 Parkwood Drive, Suite 210
Hopkinton, MA 01748
October 15, 2020
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
RE: | Spring Bank Pharmaceuticals, Inc. |
Registration Statement on Form S-4 File No. 333-248487
Request for Acceleration of Effectiveness
Ladies and Gentlemen:
In accordance with Rule 461 promulgated under the Securities Act of 1933, as amended, Spring Bank Pharmaceuticals, Inc. (the “Company”) hereby requests acceleration of the effective date of the Registration Statement on Form S-4 (File No. 333-248487), as amended (the “Registration Statement”), so that it may become effective at 5:30 p.m. Washington, D.C. time on October 19, 2020, or as soon as possible thereafter.
The Company hereby authorizes Megan N. Gates, Esq. of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. to orally modify or withdraw this request for acceleration.
The Company respectfully requests that it be notified of such effectiveness by a telephone call to Megan Gates at (617) 348-4443 and that such effectiveness also be confirmed in writing. Any questions regarding this request may be addressed to Megan Gates.
Very truly yours,
SPRING BANK PHARMACEUTICALS, INC. |
/s/ Garrett Winslow |
Garrett Winslow General Counsel and Corporate Secretary |
cc: | Spring Bank Pharmaceuticals, Inc. |
Martin Driscoll, Chief Executive Officer
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Megan N. Gates, Esq.
Melanie R. Levy, Esq.
Melissa Frayer, Esq.